Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin

Type 1 Diabetes Mellitus Clinical Trial

— DP3  

Official title:

Randomized Crossover Feasibility Study of Artificial Pancreas Device (AP) Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS) With and Without Basal and Insulin-to-Carbohydrate Bolus Initialization

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01929798
• Other study ID #: DP301
• Status: Completed
• Phase: Phase 0
• First received: August 15, 2013
• Last updated: October 20, 2015
• Start date: November 2013
• Est. completion date: November 2014

Study information

• Verified date: October 2015
• Source: William Sansum Diabetes Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to assess the performance of an Artificial Pancreas (AP) device using the Portable Artificial Pancreas System (pAPS) platform for subjects with type 1 diabetes using an insulin pump and rapid acting insulin. This proposed study is designed to compare closed-loop control with or without optimization of initialization parameters related to basal insulin infusion rates and insulin to carbohydrate (I:C) ratios for meals and snacks.

Description:

The study consists of an evaluation of the Artificial Pancreas device system during two 24-27.5-hour closed-loop phases in an outpatient/hotel environment. Prior to the closed-loop phases, each subject will undergo a 7-day data collection period consisting of his or her usual free-living conditions along with 3 meals of known carbohydrate content. Data from the insulin pump, a continuous glucose monitoring sensor (CGM), diet and exercise records will be collected during this period. These data from this 7-day period will be analyzed in order to come up with adapted basal insulin infusion rates and bolus insulin to carbohydrate (I:C) ratios.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: November 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 6 months with commercially available rapid acting insulin

• The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.

• Age 21 to 65 years

• For females, not currently known to be pregnant or nursing

• HbA1c = to 10%, as measured with DCA2000 or equivalent device

• Willing to perform the calibration of the study CGMs using a finger stick only and willing to follow instructions for insulin pump and CGM wear.

• Willing to use the study CGM and study insulin pump during closed-loop.

• Able to and agrees to avoid the following medication starting 24 hours before sensor wear through completion of the close loop study visit: acetaminophen, prednisone, and pseudoephedrine.

• An understanding of and willingness to follow the protocol and sign the informed consent.

Exclusion Criteria:

• Pregnancy (as determined by a positive blood pregnancy test performed in females of childbearing capacity during screening visit and urine test at time of admission for in-patient visit) or nursing mother.

• Females who are sexually active and able to conceive that do not use contraception.

• Any documented arrhythmias.

• Diabetic ketoacidosis in the past 6 months prior to enrollment requiring emergency room visit or hospitalization

• Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment

• Current treatment for a seizure disorder; Subjects with a history of seizures may be included in the study if they receive written clearance from their neurologist

• Active infection

• A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as cognitive deficit.

• Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation, including subjects not able to read or write.

• Coronary artery disease or heart failure. Subjects with a history of coronary artery disease may be included in the study if they receive written clearance from their cardiologist

• Presence of a known adrenal disorder

• Active gastroparesis

• If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study

• Uncontrolled thyroid disease. Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment

• Abuse of alcohol

• A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the exercise protocol

• Current use of a beta blocker medication

• Hematocrit < 30% or >55%

• A1C > 10%

• Abnormal liver or renal function (Transaminase >2 times the upper limit of normal, Creatinine> 1.5 mg/dL)

• Labs drawn at screening visit or within one month prior to screening (for other purposes) will suffice for enrollment purposes related to hematocrit

• Subject has skin conditions that, in the determination of the investigator, would preclude wearing the study devices (infusion set and sensor), in the abdomen. Examples include but are not limited to: psoriasis, burns, scaring, eczema, tattoos, and significant hypertrophy at sites of device wear; any known allergy to medical adhesives.

• Currently on long-term treatment using prednisone.

• If subject had been on short term treatment of prednisone, defer enrollment until underlying condition and prednisone treatment have resolved.

• Allergy to study drug, food or other study material.

• Clinically significant screening ECG, physical examination, laboratory test, or vital sign abnormality.

• Exposure to any investigational drug within 30 days.

• History of malignancy within the 5 years before screening (other than basal cell carcinoma).

• Currently smoking or discontinued smoking (including cigarettes, cigars, pipes) over the past 6 months.

• Highly sensitive to insulin: insulin-to-carbohydrate ratio I:C > 1:12

• Current participation in another investigational trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Device:
• portable Artificial Pancreas
The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.

Locations

Country	Name	City	State
United States	Sansum Diabetes Research Institutute	Santa Barbara	California

Sponsors (5)

Lead Sponsor	Collaborator
William Sansum Diabetes Center	Mayo Clinic, University of California, Santa Barbara, University of Padova, University of Virginia

Country where clinical trial is conducted

United States, 

References & Publications (1)

Dassau E, Brown SA, Basu A, Pinsker JE, Kudva YC, Gondhalekar R, Patek S, Lv D, Schiavon M, Lee JB, Dalla Man C, Hinshaw L, Castorino K, Mallad A, Dadlani V, McCrady-Spitzer SK, McElwee-Malloy M, Wakeman CA, Bevier WC, Bradley PK, Kovatchev B, Cobelli C, — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	time spent in safe blood glucose range	The percentage time spent in safe blood glucose range of [80-140] mg/dl will be the primary endpoint. More time spent inside the desired range will be considered successful. Expected levels are [70-180] mg/dl the 5 hours after meals and [70-150] mg/dl 3 hours after exercise.	24-hour closed-loop	Yes
Secondary	glucose level extremes and need for outside intervention	The secondary endpoint measures glucose extremes and the need for outside intervention to prevent hypoglycemia or hyperglycemia. Interventions would be insulin injections or oral carbohydrates given to the subject by the physician. No need for physician intervention will be considered a successful outcome.	24-hour closed loop	Yes

External Links

•   Results Publication